eGlint has developed the ProteoNex™ technology, a miniature biosensing device that quantifies multiple biomarkers from a small blood sample in under five minutes without the need for sample purification. This technology addresses the urgent need for rapid and cost-effective diagnostics, particularly in critical conditions like sepsis, where timely intervention can significantly reduce mortality rates.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for conditions like sepsis often require lengthy sample purification processes and can be slow, hindering timely intervention and potentially increasing mortality rates. Rapid and cost-effective diagnostic tools are needed, especially in critical care settings where immediate results can significantly improve patient outcomes.
Solution
eGlint has developed ProteoNex™, a technology that enables real-time biomarker testing directly from a small blood sample, eliminating the need for sample purification and delivering results in under five minutes. The ProteoNex™ technology is versatile, allowing it to measure combinations of virtually any biomarkers. This rapid, highly multiplexed, and quantitative approach provides clinicians with actionable insights for faster and more informed decision-making in critical conditions like sepsis. The affordable and scalable nature of the technology lowers the cost per sample and dramatically reduces the cost per biomarker, making it accessible for widespread use.
Target Audience
The primary target audience includes healthcare providers and diagnostic laboratories seeking rapid, cost-effective, and highly multiplexed biomarker testing solutions for critical conditions like sepsis.
Features
- ProteoNex™ technology quantifies virtually any biomarker from a drop of blood.
- Performs hundreds of assays simultaneously.
- Delivers results within minutes without sample purification.
- Lowers cost per sample and dramatically reduces cost per biomarker.